Baker Bros. Advisors LP Autolus Therapeutics PLC Transaction History

Baker Bros. Advisors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$4.78 - $7.96 $2.21 Million - $3.68 Million	-461,726 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$5.49 - $9.36 $1.76 Million - $3 Million	-320,457 Reduced 40.97%	461,726 $2.65 Million
Q4 2020 Feb 16, 2021	BUY	$8.13 - $12.79 $2.61 Million - $4.1 Million	320,859 Added 69.55%	782,183 $6.99 Million
Q3 2020 Nov 16, 2020	SELL	$11.64 - $16.3 $282,852 - $396,090	-24,300 Reduced 5.0%	461,324 $5.37 Million
Q2 2020 Aug 14, 2020	BUY	$5.38 - $16.14 $1.77 Million - $5.31 Million	328,851 Added 209.76%	485,624 $7.79 Million
Q4 2018 Feb 13, 2019	SELL	$24.21 - $48.01 $1.9 Million - $3.77 Million	-78,521 Reduced 33.37%	156,773 $5.15 Million
Q2 2018 Aug 14, 2018	BUY	$25.0 - $27.75 $5.88 Million - $6.53 Million	235,294 New	235,294 $6.3 Million

114

167M

34.2K

19.5K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $330M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.